{"id":25549,"date":"2025-02-05T21:08:22","date_gmt":"2025-02-05T13:08:22","guid":{"rendered":"https:\/\/flcube.com\/?p=25549"},"modified":"2025-02-05T21:08:25","modified_gmt":"2025-02-05T13:08:25","slug":"vantive-launches-as-standalone-vital-organ-therapy-company-post-carlyle-acquisition","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=25549","title":{"rendered":"Vantive Launches as Standalone Vital Organ Therapy Company Post Carlyle Acquisition"},"content":{"rendered":"\n

Vantive, formerly the Baxter Kidney Care segment, has announced its launch as a new standalone vital organ therapy company following the completion of its acquisition by funds managed by global investment firm Carlyle (NASDAQ: CG<\/a>) from Baxter International Inc. (NYSE: BAX<\/a>). This marks a significant step in Vantive’s evolution as an independent entity focused on advancing vital organ therapies.<\/p>\n\n\n\n

Background on the Acquisition and Separation<\/strong>
Baxter first revealed its separation plan in January 2023, spinning off its renal care and acute therapies businesses into an independent new company. Vantive will focus on developing and selling products for peritoneal dialysis, hemodialysis, and acute kidney injury treatment in intensive care units. This strategic move aims to enhance the company’s ability to innovate and deliver specialized solutions for patients with critical kidney conditions.<\/p>\n\n\n\n

Future Outlook<\/strong>
With the support of Carlyle, Vantive is poised to leverage its expertise in renal care and acute therapies to drive innovation and improve patient outcomes. The company’s independence allows it to focus on developing cutting-edge treatments and technologies, ultimately contributing to the advancement of vital organ therapies globally.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Vantive, formerly the Baxter Kidney Care segment, has announced its launch as a new standalone…<\/p>\n","protected":false},"author":1,"featured_media":25552,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[2163,3555,3556,1971],"class_list":["post-25549","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-baxter","tag-carlyle","tag-nasdaq-cg","tag-vantive"],"yoast_head":"\nVantive Launches as Standalone Vital Organ Therapy Company Post Carlyle Acquisition - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Vantive, formerly the Baxter Kidney Care segment, has announced its launch as a new standalone vital organ therapy company following the completion of its acquisition by funds managed by global investment firm Carlyle (NASDAQ: CG) from Baxter International Inc. (NYSE: BAX). This marks a significant step in Vantive's evolution as an independent entity focused on advancing vital organ therapies.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=25549\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Vantive Launches as Standalone Vital Organ Therapy Company Post Carlyle Acquisition\" \/>\n<meta property=\"og:description\" content=\"Vantive, formerly the Baxter Kidney Care segment, has announced its launch as a new standalone vital organ therapy company following the completion of its acquisition by funds managed by global investment firm Carlyle (NASDAQ: CG) from Baxter International Inc. (NYSE: BAX). This marks a significant step in Vantive's evolution as an independent entity focused on advancing vital organ therapies.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=25549\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-05T13:08:22+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-02-05T13:08:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/02\/0510-png.avif\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"585\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25549#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25549\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Vantive Launches as Standalone Vital Organ Therapy Company Post Carlyle Acquisition\",\"datePublished\":\"2025-02-05T13:08:22+00:00\",\"dateModified\":\"2025-02-05T13:08:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25549\"},\"wordCount\":197,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25549#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/02\\\/0510-png.avif\",\"keywords\":[\"Baxter\",\"Carlyle\",\"NASDAQ: CG\",\"Vantive\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=25549#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25549\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=25549\",\"name\":\"Vantive Launches as Standalone Vital Organ Therapy Company Post Carlyle Acquisition - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25549#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25549#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/02\\\/0510-png.avif\",\"datePublished\":\"2025-02-05T13:08:22+00:00\",\"dateModified\":\"2025-02-05T13:08:25+00:00\",\"description\":\"Vantive, formerly the Baxter Kidney Care segment, has announced its launch as a new standalone vital organ therapy company following the completion of its acquisition by funds managed by global investment firm Carlyle (NASDAQ: CG) from Baxter International Inc. (NYSE: BAX). This marks a significant step in Vantive's evolution as an independent entity focused on advancing vital organ therapies.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25549#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=25549\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25549#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/02\\\/0510-png.avif\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/02\\\/0510-png.avif\",\"width\":1080,\"height\":585,\"caption\":\"Vantive Launches as Standalone Vital Organ Therapy Company Post Carlyle Acquisition\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25549#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Vantive Launches as Standalone Vital Organ Therapy Company Post Carlyle Acquisition\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Vantive Launches as Standalone Vital Organ Therapy Company Post Carlyle Acquisition - Insight, China's Pharmaceutical Industry","description":"Vantive, formerly the Baxter Kidney Care segment, has announced its launch as a new standalone vital organ therapy company following the completion of its acquisition by funds managed by global investment firm Carlyle (NASDAQ: CG) from Baxter International Inc. (NYSE: BAX). This marks a significant step in Vantive's evolution as an independent entity focused on advancing vital organ therapies.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=25549","og_locale":"en_US","og_type":"article","og_title":"Vantive Launches as Standalone Vital Organ Therapy Company Post Carlyle Acquisition","og_description":"Vantive, formerly the Baxter Kidney Care segment, has announced its launch as a new standalone vital organ therapy company following the completion of its acquisition by funds managed by global investment firm Carlyle (NASDAQ: CG) from Baxter International Inc. (NYSE: BAX). This marks a significant step in Vantive's evolution as an independent entity focused on advancing vital organ therapies.","og_url":"https:\/\/flcube.com\/?p=25549","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-02-05T13:08:22+00:00","article_modified_time":"2025-02-05T13:08:25+00:00","og_image":[{"width":1080,"height":585,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/02\/0510-png.avif","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=25549#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=25549"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Vantive Launches as Standalone Vital Organ Therapy Company Post Carlyle Acquisition","datePublished":"2025-02-05T13:08:22+00:00","dateModified":"2025-02-05T13:08:25+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=25549"},"wordCount":197,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=25549#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/02\/0510-png.avif","keywords":["Baxter","Carlyle","NASDAQ: CG","Vantive"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=25549#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=25549","url":"https:\/\/flcube.com\/?p=25549","name":"Vantive Launches as Standalone Vital Organ Therapy Company Post Carlyle Acquisition - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=25549#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=25549#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/02\/0510-png.avif","datePublished":"2025-02-05T13:08:22+00:00","dateModified":"2025-02-05T13:08:25+00:00","description":"Vantive, formerly the Baxter Kidney Care segment, has announced its launch as a new standalone vital organ therapy company following the completion of its acquisition by funds managed by global investment firm Carlyle (NASDAQ: CG) from Baxter International Inc. (NYSE: BAX). This marks a significant step in Vantive's evolution as an independent entity focused on advancing vital organ therapies.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=25549#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=25549"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=25549#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/02\/0510-png.avif","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/02\/0510-png.avif","width":1080,"height":585,"caption":"Vantive Launches as Standalone Vital Organ Therapy Company Post Carlyle Acquisition"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=25549#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Vantive Launches as Standalone Vital Organ Therapy Company Post Carlyle Acquisition"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/02\/0510-png.avif","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/25549","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=25549"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/25549\/revisions"}],"predecessor-version":[{"id":25553,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/25549\/revisions\/25553"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/25552"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=25549"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=25549"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=25549"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}